Imbert-Bismut F
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
-
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
-
Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
-
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
-
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
-
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.
-
Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation.
-
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
-
Assessment of liver fibrosis: noninvasive means.
-
Biomarkers of liver fibrosis.
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication
-
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.
-
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
-
The use of enzyme results for liver fibrosis evaluation neccessitates standardization.
-
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
-
FibroMAX: towards a new universal biomarker of liver disease?
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
-
Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
-
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication
-
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication
-
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
-
Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores.
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.
-
A reference material for traceability of aspartate aminotransferase (AST) results.
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
-
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
-
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
-
[Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].
-
[Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest].
-
Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).
-
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
-
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.
-
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.
-
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
-
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.
-
Noninvasive prediction of fibrosis in patients with chronic hepatitis C.
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
-
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
-
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.
-
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.
-
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
-
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication